LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting

The preliminary results of Catumaxomab for advanced gastric cancer with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

LintonPharm Announces Completion of Enrollment for Stage 1 of the Global Phase Ⅲ Trial of Catumaxomab in Patients with Advanced Gastric Cancer

LintonPharm has completed the enrollment of stage 1 of the global phase III trial. This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis.

LintonPharm Announces First Patient Dosed in Phase Ⅰ/Ⅱ Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

The first patient has been dosed in the Phase Ⅰ/Ⅱ clinical trial program for catumaxomab , a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin.

Authorization from China Health Authority (NMPA) to Proceed with a Phase Ⅰ/Ⅱ Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

NMPA authorized the company to proceed with a Phase Ⅰ/Ⅱ clinical trial evaluating the safety and efficacy of catumaxomab in patients with NMIBC whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure.

First Patient Dosed in Stage 1 of the Global Phase Ⅲ Trial of Catumaxomab for the Treatment of Gastric Cancer on 6th October

Dosing of the first patient with gastric cancer in the stage I of the phase III trial of catumaxomab in Taiwan (China) on 6th October. This global phase III trial is designed to evaluate the safety and efficacy of an intraperitoneal infusion of the catumaxomab in patients with gastric cancer peritoneal carcinomatosis who are not suitable for systemic chemotherapy.